Monday, November 30, 2020 11:10:26 AM
Warfaretrader is obviously a seasoned investor and it’s a benefit to this board to have him take time to honestly point out all the potential trappings of any company trading at these levels. It's information that can be formulated when an investor feels a stock is reaching a critical stage on whether it should be held or sold.
My own personal assessment of CLWD at this stage is heavily weighted towards SWARM being developed into full SaaS. Is all the information implying this move provided by the company at this point all hype? There lies the million dollar question and something each individual has to ask themselves. Based on my exposure I’m familiar with what goes into the conversion and well aware of the many variables that can arise as part of the process. The amount of time it’s taken to this juncture isn’t unreasonable when you factor in the current developmental phase of the company. If this was a company trading on a major exchange with plenty of funding and skilled engineers at their disposal it would certainly take less time. The flip side being… you wouldn’t have the opportunity to buy shares under a penny and that’s part of what underlies the “should or shouldn’t I” factor when it comes to making an investment decision in CLWD.
On the surface—First three quarter revenue totals for 2020 exceeding 2019’s; minimal dilution up to this point for an OTC company; a share price well below 1X’s multiple; servicing an industry with tremendous upside; full SaaS conversion which could lead to sizeable top-line revenue growth increase; impressive clientele list; and a very attractive partnership/merger candidate. All this reflects potential catalysts to appease both the longer and shorter term investor.
Recent AIAD News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/01/2024 10:45:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 09:35:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2024 10:50:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2024 10:50:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2024 10:49:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2024 10:48:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2023 06:28:38 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/20/2023 08:29:14 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2023 08:05:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/18/2023 09:00:58 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM